NCT04249869 is a Phase 1, PHASE2 clinical trial of VGH-AD1 in Alzheimer Disease, sponsored by Taipei Veterans General Hospital, Taiwan.

Who is sponsoring NCT04249869?

NCT04249869 is sponsored by Taipei Veterans General Hospital, Taiwan.

What drugs are being tested in NCT04249869?

Interventions in NCT04249869: VGH-AD1.

What condition does NCT04249869 study?

NCT04249869 studies Alzheimer Disease.

Is NCT04249869 still recruiting?

NCT04249869 is currently status unknown. Last updated 31 January 2020.

Last reviewed 2020-01-31 · How we verify

NCT04249869

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy of Traditional Chinese Herbal Medicine for Alzheimer's Disease

Status unknown Phase 1, PHASE2 Last updated 31 January 2020

What this trial tests

Phase 1, PHASE2 trial testing VGH-AD1 in Alzheimer Disease in 28 participants. Status unknown.

Timeline

1 February 2020

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Taipei Veterans General Hospital, Taiwan
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	28
Start date	1 February 2020
Primary completion	31 December 2020
Estimated completion	31 December 2020

Drugs / interventions tested

VGH-AD1 — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Taipei Veterans General Hospital, Taiwan

Who can join

65 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, double-blinded, placebo-controlled, crossover clinical trial aims to investigate the effect of VGH-AD1, a scientific Chinese medicine powder prescription, on patients with Alzheimer's disease.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2022.
Cummings J, Lee G, Nahed P, Kambar MEZN, et al · · 2022 · cited 369× · PMID 35516416 · DOI 10.1002/trc2.12295
Alzheimer's disease drug development pipeline: 2020.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2020 · cited 350× · PMID 32695874 · DOI 10.1002/trc2.12050
Alzheimer's disease drug development pipeline: 2021.
Cummings J, Lee G, Zhong K, Fonseca J, et al · · 2021 · cited 312× · PMID 34095440 · DOI 10.1002/trc2.12179
Therapeutic approaches for improving cognitive function in the aging brain.
Chen L, Jiao J, Zhang Y. · · 2022 · cited 26× · PMID 36570840 · DOI 10.3389/fnins.2022.1060556
Combining human and machine intelligence for clinical trial eligibility querying.
Fang Y, Idnay B, Sun Y, Liu H, et al · · 2022 · cited 21× · PMID 35426943 · DOI 10.1093/jamia/ocac051
Natural Products from Plants and Algae for Treatment of Alzheimer's Disease: A Review.
Klose J, Griehl C, Roßner S, Schilling S. · · 2022 · cited 7× · PMID 35625622 · DOI 10.3390/biom12050694
Recent advancements in the role of phytochemicals and medicinal plants in prophylaxis and management of Alzheimer's disease.
Mishra A, Krishnamurthy S. · · 2024 · PMID 39386232 · DOI 10.22038/ijbms.2024.77760.16826

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Taipei Veterans General Hospital, Taiwan trials

Trials by the same sponsor.

NCT07463443 — Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Stud · NA · not yet recruiting
NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
NCT07362134 — Pulsed-Field Ablation for Recurrent Atypical Atrial Flutter · NA · enrolling by invitation
NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
NCT07344207 — GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04249869 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taipei Veterans General Hospital, Taiwan
Last refreshed: 31 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04249869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing